Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Analytical Advances: The Protein ID Autobahn ? Automated Nanoelectrospray Mass Spectrometry
Author(s)Gary Schultz
by Gary Schultz, Advion BioSciences
Advertisement
Articles in this issue
almost 24 years ago
Inside Washington: Major Changes Ahead for FDAalmost 24 years ago
Bioinformatics Databases ? Questions of Copyrightalmost 24 years ago
European Editor's Report ? An Industry Comes of Agealmost 24 years ago
Guest Editorial: Back to the Beginningalmost 24 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationalmost 24 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsAdvertisement
Related to this article
At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
3
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
4
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
5